Singapore pharmaceuticals

The Republic may not have a major player to call its own, but licensing deals and early-stage breakthroughs can still count as wins

This surprised private-sector economists who had expected a 6.7% growth

The amount surpasses the goal of S$5 million; new shares issued at S$0.10 apiece

The placement price represents a discount of 9.7% to the volume weighted average price of S$0.1107 per share

This brings the counter up 408% in the year to date

Talks on a preferential tariff arrangement for Singapore’s pharmaceutical exports to the US continue, says Minister of State for Trade and Industry

Drugmakers are ‘continuing to clarify’ to better understand the conditions and criteria tied to the new taxes

More listings will keep the Republic’s capital markets robust, develop an ecosystem and strengthen its regional hub status 

Without exemptions, the effective tariff rate on the Republic’s shipments could exceed 30%, compared with 4% now